Covaxin safe, shows minimal side-effect: Lancet on Ph-2 trial

New Delhi, March 9

Advertisement

In a major boost to the safety profile of Bharat Biotech and ICMR-made Covaxin, the leading medical journal, The Lancet, on Tuesday published the Phase-2 trial results of the vaccine, saying it was safe and immunogenic with minimal side-effects.

Stock up pvt facilities for speedy vaccination: PMO

New Delhi: The Principal Secretary to PM Narendra Modi on Tuesday directed states to stock up private facilities with vaccine supplies for 15 to 28 days for offering online booking slots to people. TNS

76 +ve cases in HP’s Akal Academy in week

Solan: Baru Sahib-based Akal Academy and two buildings in its precincts at Lana Bhalta village in Sirmaur district have been declared containment zones after 76 nursing students tested positive this week. 

In a study, The Lancet — Infectious Diseases Journal also said the efficacy could only be determined by the Phase-3 trials. However, the interim results of the Phase-3 trials of Covaxin have since been released and the vaccine has shown 81 per cent efficacy.

The research published today involved 380 individuals (children and adults aged between 12 and 65 years) who participated in the Covaxin Phase-2 trials between September 5 and 12, 2020.

Results showed higher (two-fold) neutralising antibodies in the Phase-2 trials as compared to the Phase-1.

Meanwhile, India today crossed a milestone in vaccine delivery by administering over 20 lakh doses in a day even as the daily new cases fell below 16,000 for the first time in four days. Maharashtra, Kerala, Punjab, Tamil Nadu, Gujarat and Karnataka continued to report a surge in the daily new cases. — TNS